Cargando…
Targeting IL-4 and IL-13 Receptors on Eosinophils in CRSwNP Patients: The Clinical Efficacy of Dupilumab
Chronic rhinosinusitis with nasal polyposis (CRSwNP) is an inflammatory disease linked to type 2 inflammation. Several biologics have demonstrated therapeutic potential for the treatment of this pathology in which IL-4, IL-5 and IL-13 represent the major cytokines involved in the control of eosinoph...
Autores principales: | Piazzetta, Giovanna Lucia, Lobello, Nadia, Chiarella, Emanuela, Rizzuti, Alberta, Pelaia, Corrado, Pelaia, Girolamo, Lombardo, Nicola |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10532854/ https://www.ncbi.nlm.nih.gov/pubmed/37763171 http://dx.doi.org/10.3390/jpm13091404 |
Ejemplares similares
-
Spotlight on a Short-Time Treatment with the IL-4/IL-13 Receptor Blocker in Patients with CRSwNP: microRNAs Modulations and Preliminary Clinical Evidence
por: Mimmi, Selena, et al.
Publicado: (2022) -
Eosinophil Cationic Protein Variation in Patients with Asthma and CRSwNP Treated with Dupilumab
por: Ledda, Andrea Giovanni, et al.
Publicado: (2023) -
Rapid and Continuing Improvements in Nasal Symptoms with Dupilumab in Patients with Severe CRSwNP
por: Bachert, Claus, et al.
Publicado: (2022) -
Olfaction Recovery following Dupilumab Is Independent of Nasal Polyp Reduction in CRSwNP
por: Cantone, Elena, et al.
Publicado: (2022) -
Measuring Nasal Patency and the Sense of Smell in CRSwNP Patients Treated with Dupilumab
por: Ottaviano, Giancarlo, et al.
Publicado: (2023)